levated blood pressure is closely related to increase in cardiovascular death from events like stroke, myocardial infarction, and chronic renal failure 1 and is defined as one of the risk factors for the metabolic syndrome. 2, 3 Other risk factors include insulin resistance, hyperglycemia, and elevated serum triacylglycerol, which are conditions that are improved in rats after treatment with the modified fatty acid tetradecylthioacetic acid (TTA). 4 The pleiotropic effects of TTA seem to be mediated through both peroxisome proliferator-activated receptor (PPAR)-dependent and PPAR-independent mechanism 4 and include changes in the fatty acid composition of both liver and serum in rats. [5] [6] [7] Based on these potential possibilities to change composition of the metabolic system, and because the fatty acid composition of cholesteryl ester and phospholipids in serum has been related to the blood pressure level in humans, 8 -10 we examined the effect of TTA on hypertension in the present study.
An inducible model of high blood pressure is the 2-kidney, 1-clip (2K1C) hypertension model, where the increased blood pressure is induced after clipping of one renal artery. This is an angiotensin II-dependent model of hypertension with increased level of plasma renin and angiotensin, and hypertension is usually established 3 to 4 weeks after clipping. 11 Long-term 2K1C hypertension is followed by organ damage as enlarged heart and damage of the nonclipped kidney with increased urinary protein excretion and declining glomerular filtration rate. 11 The intention of the present study was to examine the effect of TTA on blood pressure in 2K1C hypertensive rats, a model without the other risk factors of the metabolic syndrome. Our working hypothesis was that TTA would interfere with the renin-angiotensin system in this high-renin model of hypertension and reduce the blood pressure through lowering of the plasma renin activity. Because TTA is reported to change the fatty acid composition, we investigated the relation between the fatty acid composition and 8-iso-prostaglandin (PG)F2␣ to blood pressure in 2K1C hypertensive rats.
Methods
An expanded Methods section can be found in an online supplement (available at http://hyper.ahajournals.org).
Animals
The protocol was approved by the Norwegian State Board for Biological Experiments With Living Animals. Male Wistar rats (Møllegaard Breeding Laboratory, Ejby, Denmark), weighing 180 to 200 g at the start of the experiment, were used for establishing 2K1C hypertension.
Two experiments were performed. In the first experiment, TTA treatment was started either at the day of clipping or 5 weeks after clipping when the hypertension was established and compared with untreated 2K1C rats. The rats were killed 12 weeks after clipping. In the second experiment, TTA treatment was started at the day of clipping and compared with untreated 2K1C rats, and the rats were killed 6 months after clipping. The systolic blood pressure was measured by means of the tail-cuff method (UGO BASILE) in unanesthetized rats.
Real-Time Quantitative RT-PCR
Total RNA was purified from frozen tissue, and the mRNA levels of renin, angiotensinogen, PPAR␣, PPAR␦, and PPAR␥ were determined by relative quantification using the standard curve method and normalized to 18S rRNA.
Analysis of Vasoactive Substances and Lipids
The renin activity and the concentration of angiotensin II were measured in plasma, whereas triacylglycerol, cholesterol, albumin, and creatinine levels were measured in serum. Urine was collected for 24 hours, and the urinary excretion of 8-iso-PGF2␣ and proteins were measured. The fatty acids composition in serum and liver were analyzed.
Enzyme Activities in Liver
The activities of carnitine palmitoyltransferase-II 12 and fatty acylcoenzyme A (CoA) oxidase 13 were measured in hepatic postnuclear fraction.
Light Microscopy
One-hundred randomly sampled glomeruli were analyzed regarding segmental or global sclerosis and podocytes with adsorption droplets and/or pseudocysts. Twenty microscopic fields were investigated for tubulointerstitial damage. Glomerular sclerosis and tubulointerstitial damage were assessed using a semiquantitative scoring system (0 to 4): grade 0 indicates no lesions, grade 1 indicates lesions in Ͻ25%, grade 2 indicates lesions in 25% to 50%, grade 3 indicates lesions in 50% to 75%, and grade 4 indicates lesions in (almost) the entire capillary tuft area/tubulointerstitial area. Atrophy in the clipped kidney was semiquantitatively graded (0 to 3): grade 0 indicates no atrophy, grade 1 indicates slight atrophy, grade 2 indicates moderateto-marked atrophy, and grade 3 indicates global atrophy.
Statistical Analysis
Data are presented as meanϮSEM. The data were evaluated by a 2-sample variance Student's t test (2-tailed distribution).
Results
In the untreated 2K1C rats, hypertension was established 3 to 4 weeks after clipping and was stable throughout the rest of the observation period of 12 weeks (Figure 1 ). TTA treatment from the time of clipping attenuated the development of hypertension in 2K1C rats (Figure 1 ). Twelve weeks after clipping, the systolic blood pressure in the untreated group was 181Ϯ3 mm Hg, whereas the systolic blood pressure in the TTA-treated group was 150Ϯ3 mm Hg (PϽ0.001; Figure  1 ). When TTA treatment was started 5 weeks after clipping, the systolic blood pressure was reduced from 168Ϯ9 mm Hg to 155Ϯ5 mm Hg (PϽ0.05) within 2 weeks, which is similar to that of rats treated with TTA from the time of clipping (Figure 1) .
TTA treatment reduced the renin mRNA level in the clipped kidney by Ͼ50% (PϽ0.05), but TTA had no effect on the renin mRNA level in the nonclipped kidney, where this level is normally very low (Figure 2A) . The renin mRNA level was significantly higher in the clipped kidney compared with the nonclipped kidney independent of treatment regime (PϽ0.01; Figure 2A ). The plasma renin activity at the time of clipping was equal in untreated and TTA-treated rats ( Figure  2B ). Twelve weeks after clipping, the plasma renin activity was markedly increased in the untreated rats but was not changed in the TTA-treated rats ( Figure 2B ). The plasma level of angiotensin II tended to decrease in TTA-treated rats ( Figure 2C ), but this was not significant (Pϭ0.06). The mRNA level of angiotensinogen, which is a precursor of angiotensin II, was reduced in epididymal white adipose tissue after TTA treatment ( Figure 3A ), but this level was increased in liver by TTA ( Figure 3B ).
Circulating fatty acids are reported to interfere with blood pressure, 8 -10 and it was, therefore, of interest to see how the fatty acid composition of serum was affected by TTA. TTA treatment increased the levels of palmitoleic acid, oleic acid, and icosatrienoic acid, but the levels of palmitic acid and stearic acid were unchanged in serum (Table 1 ). In addition, the level of linoleic acid and all of the omega-3 polyunsaturated fatty acids (PUFAs) were reduced after TTA treatment ( Table 1) .
The isoprostane 8-iso-PGF2␣ is formed nonenzymatically from the attack of a superoxide radical on esterified arachidonic acid. Although the level of arachidonic acid in serum was not affected (Table 1) , the urinary excretion of 8-iso-PGF2␣ was significantly decreased after TTA treatment ( Figure 4 ).
The effect of TTA on the fatty acid composition in liver was similar to that seen in serum (data not shown). TTA and its ⌬9 desaturated metabolite TTA:1n-8 were recovered in both serum (Table 1 ) and liver (data not shown) of TTAtreated rats.
TTA treatment significantly reduced the serum levels of triacylglycerol and cholesterol (Table 2) . Concomitant with this, the activities of carnitine palmitoyltransferase-II and fatty acyl-CoA oxidase were increased ( Table 2 ), suggesting that TTA increased the capacity for fatty acid oxidation. However, TTA did not significantly change the mRNA levels of PPAR␣, PPAR␦, or PPAR␥ in clipped or nonclipped kidneys (data not shown). To evaluate the role of TTA in the prevention of organ damage induced by hypertension, 2K1C rats were treated with TTA for 6 months from the time of clipping. At the end of this long-term study, the systolic blood pressure was 213Ϯ6 mm Hg in the untreated rats and 168Ϯ8 mm Hg in the TTA-treated rats (PϽ0.001). The urinary protein excretion was increased Ͼ5-fold (175Ϯ40 versus 29Ϯ4 mg/24 h Ϫ1 ; PϽ0.01) during the experiment ( Figure 5A ), accompanied by decreased serum albumin level (34Ϯ1.2 versus 46Ϯ2 gL Ϫ1 ; PϽ0.01; Figure 5B ). However, serum creatinine was unchanged at the end of the experiment ( Figure 5C ). The urinary protein excretion ( Figure 5A ), serum albumin level ( Figure  5B ), and serum creatinine ( Figure 5C ) were not affected during the experiment in the TTA-treated rats. The body weight and the heart weight were significantly lower in the TTA-treated rats, whereas TTA treatment did not affect the kidney weights (Table 3) .
TTA-treated rats clearly developed less morphological damage in the nonclipped kidney 6 months after clipping compared with untreated rats (Figure 6 ). There were only minor arterial and arteriolar changes in the nonclipped kidney in TTA-treated rats in contrast to marked vascular wall changes with media hypertrophy, intima proliferation, hyalinosis, and fibrinoid necrosis in untreated rats. Hypertensionassociated glomerular changes in the nonclipped kidney (adsorption droplets, pseudocysts, segmental, and global sclerosis; Figure 7 ) as well as tubulointerstitial damage were significantly reduced in TTA-treated rats (Table 4) . There was no significant difference in the atrophy score of the clipped kidney in untreated and TTA-treated rats (Table 4) .
Discussion
Elevated blood pressure is closely related to increase in cardiovascular death from events like stroke, myocardial infarction, and chronic renal failure. 1 In the present study, we wanted to examine the effect of TTA on secondary hypertension induced by clipping of one renal artery to see whether TTA could interfere with the renin-angiotensin system, the lipid metabolism, and development of hypertension.
In the present article, we show for the first time that TTA attenuated the development of hypertension in 2K1C when TTA was given from the day of clipping, and, in addition, TTA reduced the blood pressure when hypertension was established. In agreement with previous findings, 12 weeks after clipping, the clipped kidney contained a higher level of renin mRNA than the nonclipped kidney, as shown previously. 14 In addition, TTA treatment had no effect on the renin mRNA level in the nonclipped kidney, but markedly reduced this level in the clipped kidney. This was accompanied by reduced plasma renin activity and a strong tendency to decrease the plasma angiotensin II level by TTA. Thus, regulation of the renin-angiotensin system seems to be important for the effect of TTA on 
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blood pressure by reducing the production of angiotensin II, which is the main vasoconstrictor in 2K1C hypertension. Activation of PPAR␥ has been reported to decrease the expression of the angiotensin-II type I receptor, 15, 16 but although TTA is a pan-PPAR ligand, 4 no change was seen in the mRNA level of PPAR␥ in clipped or nonclipped kidneys after TTA treatment. Hypertension is one of the complications in obesity, and the adipose angiotensinogen gene expression has been shown to play a role in both adipose tissue development and hypertension of obese patients, [17] [18] [19] representing a link between obesity and hypertension. The increased activities of carnitine palmitoyltransferase-II and fatty acyl-CoA oxidase in liver of TTA-treated 2K1C rats suggested that both the mitochondrial and the peroxisomal ␤-oxidation were increased, and this was accompanied by reduced serum triacylglycerol, as demonstrated previously in normotensive rats. 20 The increased ␤-oxidation of fatty acids by TTA could lead to lowered amounts of the adipose tissue, as we have found previously, 21 a finding that may contribute to reduced production of angiotensinogen. 22 Interestingly, TTA seemed to have a tissue-specific effect on the gene expression of angiotensinogen, because the mRNA level of angiotensinogen was reduced in white adipose tissue and increased in liver. This is in line with findings by others showing that high-fat feeding differently affects the mRNA level of angiotensinogen in adipose tissue and liver of mice. 23 Because fat surrounds many of the muscular arteries, changes in adipose angiotensinogen mRNA level and, thus, the production of angiotensin II might affect the systemic vascular resistance. 24 Olive oil contains a high amount of oleic acid and is reported to decrease blood pressure in humans. [25] [26] [27] Here we show that the attenuation of hypertension after TTA treatment is accompanied by increased levels of oleic acid and its metabolites palmitoleic acid and icosatrienoic acid, probably because of increased ⌬9 desaturase activity. 28 An elevated level of palmitic acid 9 and a reduced level of stearic acid 8 in serum cholesteryl esters are associated with higher risk of hypertension; however, in the present study, no change was seen in the serum levels of these fatty acids.
Dietary supplementation with omega-3 PUFAs, such as eicosapentaenoic acid and docosahexaenoic acid, lowers blood pressure and prevents the development of hypertension, 29 -32 possibly because of the ability of omega-3 PUFAs to replace and, thus, reduce the cellular membrane levels of arachidonic acid. 33 Despite the attenuation of 2K1C hypertension by TTA treatment, the level of all of the omega-3 acids in serum was reduced, probably as a result of the increased mitochondrial and peroxisomal ␤-oxidation. 12 Reduced serum linoleic acid is observed in patients and experimental animal models with hypertension, 9,10 whereas a high level of dihomo-␥-linolenic acid and arachidonic acid in serum cholesteryl esters has been shown to be associated with increased risk of hypertension. 8, 9 In the present experiment, TTA decreased the level of linoleic acid and increased the level of dihomo-␥-linolenic acid, whereas no change was seen in the level of arachidonic acid. Linoleic acid is the essential precursor of the longer omega-6 PUFAs, and arachidonic acid can be synthesized from linoleic acid via ␥-linolenic acid and dihomo-␥-linolenic acid in liver. The biosynthesis of arachidonic acid is catalyzed by ⌬5 and ⌬6 desaturases, and we have found previously that TTA increases the level of arachidonic acid in normotensive rats 34 and upregulates the gene expression of these desaturases in rat liver (O.G. Gudbrandsen, T.H. Røst, R.K. Berge, unpublished data, 2006). Because the rate-determining desaturases and intermediates are increased, it may be reasonable to assume that the generation of arachidonic acid was increased. However, because no change was seen in arachidonic acid in serum or liver, the conversion of arachidonic acid to other compounds, such as prostaglandins, may be increased by TTA in the present experiment.
The isoprostane 8-iso-PGF2␣ is produced by free-radical peroxidation of esterified arachidonic acid and is an extremely potent renal vasoconstrictor. 35, 36 In the present study, the attenuation of hypertension in 2K1C by TTA was associated with reduced excretion of 8-iso-PGF2␣ in urine, whereas the level of arachidonic acid in serum and liver was unchanged. The lack of correlation between 8-iso-PGF2␣ and arachidonic acid may be explained by changes in the peroxisomal ␤-oxidation capacity, because 8-iso-PGF2␣ can be oxidized by peroxisomes. 37 Because the peroxisomal ␤-oxidation activity was enhanced by TTA, TTA may protect 2K1C rats from the vasoconstrictive effect of 8-iso-PGF2␣ by increasing the peroxisomal ␤-oxidation.
A blood pressure-lowering drug should also reduce or inhibit development of organ damage. Six months after clipping, TTA treatment not only attenuated hypertension but also abolished proteinuria, in contrast to untreated 2K1C rats, which developed heavy proteinuria and a decline in serum albumin. TTA also protected the heart, because the heart weight was lower than in untreated rats. Most important, the morphological changes were markedly attenuated during TTA treatment in the nonclipped kidney, whereas the clipped kidney was protected by the clip and showed similar changes in untreated and TTA-treated rats.
Perspectives
We have shown previously that TTA improve several risk factors of the metabolic syndrome, such as insulin resistance, hyperglycemia, and hyperlipidemia, in rats. In the present study, we show for the first time that TTA also prevented the development of hypertension and organ damage in rats. This effect seems to be mediated through the renin-angiotensin system, which plays a major role in human types of hypertension. The combination of lipid-lowering effect and blood pressure reduction makes TTA a promising drug, because high lipid levels and high blood pressure are major challenges in clinical practice. A further perspective will be to examine the effect of TTA in genetic hypertension where the reninangiotensin system is less upregulated than in renal hypertension. Because the blood pressure-lowering effect of TTA seems to be mediated at least partly via the renin-angiotensin system, further studies on the effect of TTA in rat models with normal renin levels, such as the spontaneously hypertensive rats, will be performed. 
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None. TTA was synthesized as previously described 3 Two experiments were performed. In the first experiment, rats were killed 12 weeks after clipping, and the systolic blood pressure and serum lipids were studied in two groups of TTA treated 2K1C rats (N=10) using untreated 2K1C rats (N=10) as controls.
Methods
Animals and treatment
In the first group, TTA treatment was started at the day of clipping. In the second group, TTA treatment was started five weeks after clipping when the hypertension was established.
In the second experiment, rats were killed six months after clipping. In this experiment the effect of long-term treatment of TTA in 2K1C rats (N=10) was studied by measurements of the systolic blood pressure, urinary protein excretion, renal morphological changes and change in heart weight using untreated 2K1C rats (N=9) as controls.
Measurements of systolic blood pressure
The systolic blood pressure was measured by means of the tail-cuff method (UGO BASILE) in unanaesthetized rats. The rats were prewarmed to 35ºC in a cupboard for 10 min.
Real-time quantitative RT-PCR
Total RNA was purified from frozen kidneys using RNeasy Midi Kit (Qiagen, Hilden, Germany) and from epididymal white adipose tissue and liver using RNeasy Mini Kit 
Plasma renin activity and angiotensin II
Plasma renin activity was determined using a GammaCoat Plasma Renin Activity 125 I radioimmunoassay kit (DiaSorin, Stillwater, MN) for quantitative determination of generated angiotensin I. The analysis was performed following the manufacturers' protocols.
Angiotensin II in plasma was measured using a radioimmunoassay kit from Phoenix Peptide (Belmont, California). The blood samples were collected on EDTAaprotinin vacutainer tubes, gently rocked to inhibit the activity of proteinases and centrifuged at 1,600 x g for 15 minutes at 4ºC. The plasma was collected and kept at -80ºC. The analysis was performed following the manufacturers' protocols.
Analysis of fatty acids and lipids
Fatty acids in serum and liver were methylated and quantified as previously described 4, 5 .
Serum levels of triacylglycerol and cholesterol were measured on the Hitachi 917 system (Roche, Germany) using the appropriate kits from Bayer (Tarrytown, NY).
Enzyme activities in liver
Frozen livers were homogenized and fractionated 6 , and the activities of carnitine palmitoyltransferase (CPT)-II 7 and fatty acyl-CoA oxidase 8 were measured in the postnuclear fraction.
Light microscopy
The kidneys were perfused in vivo via the abdominal aorta with 0.9% saline. Transversal slices of the clipped and non clipped kidneys were fixed with 4% buffered formaldehyde 
Urinary levels of 8-iso-PGF2 and proteins
Urine was collected for 24 hours while the rats were in metabolic cages. Urinary excretion of 8-iso-PGF2 was measured using a radioimmunoassay kit from Izotop (Budapest, Hungary). Urinary protein excretion was measured with the pyrogallol redmolybdate method of Watanabe et al. 9 .
Measurements of albumin and creatinine in serum
Serum albumin and creatinine were measured on the Hitachi 917 system using the appropriate kits from Roche.
Statistical analysis
Data are presented as mean ± SEM. The data were evaluated by a two-sample variance Student's t test (two-tailed distribution).
